News | Hephaistos Pharma

HEPHAISTOS Awarded Best Biotech Pitch at HTID 2025

We are delighted to announce that HEPHAISTOS-Pharma has been honored with the Best Pitch nomination in the Biotech category at the 2025 HealthTech Innovation Days (HTID), organized by HealthTech For Care. HTID is one of Europe’s premier health-innovation gatherings,...

“Golden Ticket” award for HEPHAISTOS from Amgen France and BioLabs Hôtel-Dieu

HEPHAISTOS-Pharma has the honor to be a winner of a Golden Ticket from Amgen France x BioLabs Hôtel-Dieu in Paris. We have won one year of free residency at BioLabs Hôtel-Dieu and personalized mentorship from Amgen experts to accelerate the development of our...

HEPHAISTOS laureate of the HACKATHON against childhood cancer

HEPHAISTOS-Pharma was laureate of the Hack4Hope, the hackathon against pediatric cancer following a great day of speed dating with pharmas, patients’ associations and experts in childhood cancer The jury was composed of experts in Oncology and Childhood cancer from...

HEPHAISTOS secures €10.3 M to reach the clinical stage

HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round, securing a total of €10.3 million from investors and non-dilutive financing. €4.5M seed round led by Elaia with xista sciences ventures, Fondation Fournier-Majoie, Noshaq, Angels Santé and Femmes Business...

Frederic CAROFF will attend BIO Europe Spring in Barcelona

Our CEO, Frederic CAROFF will be attending BIO-Europe Spring 2024 in Barcelona from March 18th to 20th. He will meet series A investors interested in Oncology biotech companies developing game-changing immunotherapy platform. He will also discuss with Pharmaceutical...

HEPHAISTOS-Pharma secures a €2 million seed round

HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq 1st institutional round for HEPHAISTOS-Pharma, getting on track to bring its lead product ONCO-Boost to the clinic. ONCO-Boost is a novel class of TLR4...

HEPHAISTOS Laureate of the SANOFI Golden Ticket mRNA

We are pleased to announce that HEPHAISTOS-Pharma has been awarded a Sanofi’s Golden Ticket 2023, winning a year’s free lab space at BioLabs @Hôtel-Dieu (France) to explore the application of their technology in developing new effective adjuvantation for mRNA...

EIC accelerator Grant Competition Winner

We are very proud to announce that we are winners of the #EIC_Accelerator grant from the European Innovation Council October 30th 2023. Winners of the EIC accelerator grant have been announced. 47 winning innovative projects have been awarded all over Europe among...

iNov BPIFrance 2030 Competition Winner

We are very proud to announce that we are winners of the #iNov France2030 Innovation Competitions For this 9th edition, 53 winning innovative projects will be supported by the State via #France2030 for a total amount of €56.3M. The i-Nov innovation competition aims to...

Orphan Drug Designation

The European Medicines Agency (EMA) has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma. Paris, France, September 1st, 2022, 7:00 pm CET. HEPHAISTOS-Pharma a French Biotech company developing a new class of...